Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Grows By 3,625.0%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 596 shares, a growth of 3,625.0% from the April 30th total of 16 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 6,288 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Ascentage Pharma Group International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International during the third quarter valued at $96,000. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth about $204,000. Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the 3rd quarter valued at about $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, XY Capital Ltd boosted its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares in the last quarter.

Ascentage Pharma Group International Price Performance

AAPG stock traded up $0.08 during trading on Friday, reaching $19.96. The company had a trading volume of 12,802 shares, compared to its average volume of 4,139. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a 52 week low of $18.56 and a 52 week high of $48.45. The business has a 50 day moving average of $23.15 and a 200 day moving average of $25.82.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million during the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International will post -1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

AAPG has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat.com, Ascentage Pharma Group International presently has an average rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.